摘要
目的:研究4种市售发酵虫草菌粉胶囊中的寡糖成分。方法:首先应用高效薄层色谱(HPTLC)对4种市售发酵虫草菌粉胶囊(百令胶囊、金水宝胶囊、宁心宝胶囊和心肝宝胶囊)寡糖成分进行初步分析,展开剂为正丁醇-异丙醇-乙酸-水(6∶11∶3∶4),显色剂为苯胺-二苯胺-磷酸;再采用HPTLC-MS确定寡糖聚合度,质谱选用正离子模式,质量范围m/z 100~1 500;最后结合淀粉酶酶解-HPTLC分析确定主要糖苷键类型。结果:4种市售发酵虫草菌粉胶囊中,除宁心宝胶囊外,其他3种发酵虫草菌粉胶囊均基本不含寡糖类成分;HPTLC-MS结果显示,宁心宝胶囊样品HPTLC中Rf=0.53、0.48、0.40、0.32、0.27、0.22和0.18处的条带相对分子质量分别约为342、342、504、666、828、991、1 153,分别对应二糖及二糖至七糖;淀粉酶酶解结果提示:宁心宝胶囊中寡糖主要是α-1,4-葡聚寡糖。结论:4种市售发酵虫草菌粉胶囊中,仅宁心宝胶囊含相对多的寡糖类成分,且主要为α-1,4-葡聚寡糖,其产生可能与菌种和/或生产工艺有关。
Objective:To investigate oligosaccharides in four commercial fermented Cordyceps mycelia powder capsules.Methods:HPTLC was employed for preliminary analysis of oligosaccharides in four commercially available fermented Cordyceps mycelia powder capsules(Bailing capsules,Jinshuibao capsules,Ningxinbao capsules and Xinganbao capsules).TLC developing solvent was 1-butanol-isopropanol-water-acetic acid(6:11:3:4)and colorized with diphenylamine-aniline-phosphoric acid reagent.Then HPTLC-MS was applied to determine the degree of polymerization in positive ion mode with mass range of m/z 100-1500.Finally,the major glycosidic linkages were determined in combination of amylase digestion and HPTLC analysis.Results:Among the four commercially available fermented Cordyceps mycelia powder capsules,except Ningxinbao capsules,the other three fermented Cordyceps mycelia powder capsules were almost free of oligosaccharides;HPTLC-MS results showed that the molecular mass of the bands at with Rfs of 0.53,0.48,0.40,0.32,0.27,0.22 and 0.18 in Ningxinbao capsules were about 342,342,504,666,828,991,1153,corresponding to disaccharides and disaccharides to heptasaccharides,respectively;the results of amylase digestion suggested that the oligosaccharides in Ningxinbao capsules were mainlyα-1,4-gluco-oligosaccharides.Conclusion:Among the four commercially available fermented Cordyceps mycelia powder capsules,only Ningxinbao capsules contain relatively high amount of oligosaccharides,and they areα-1,4-gluco-oligosaccharides,the production of which may be derived from different strains and/or production process.
作者
陈芷馨
朱宝杰
赵鹏
杨明
李绍平
赵静
CHEN Zhi-xin;ZHU Bao-jie;ZHAO Peng;YANG Ming;LI Shao-ping;ZHAO Jing(State Key Laboratory of Quality Research in Chinese Medicine,University of Macao,Macao 999078,China;Joint Laboratory of Chinese Herbal Glyco-engineering and Testing Technology,University of Macao,Macao 999078,China;Jiangxi JeMinCare Group Co.,Ltd.,Nanchang 330029,China)
出处
《药物分析杂志》
CAS
CSCD
北大核心
2023年第7期1129-1134,共6页
Chinese Journal of Pharmaceutical Analysis
基金
澳门科学技术发展基金项目(0017/2019/AKP)
广东省重点领域研发计划(2020B1111110006)
澳门大学科学研究基金项目(MYRG2018-00083-ICMS/MYRG2019-00128-ICMS/CPG2022-00014-ICMS)。